已發(fā)表論文：（*為通訊作者，#為共同第一作者） （1）黃堯;黃新輝;黎蘊(yùn)通;邢曉華;王英超;曾永毅;曾金華;劉小龍;劉景豐*; 肝細(xì)胞癌組織中己糖激酶-2蛋白的表達(dá)及臨床意義, 中華消化外科雜志, 2017,16(2):170-176. （2）Huang Y; Liang D; Liu J; Zeng J; Zeng Y; The Breakthroughs in Cancer Immune Ch eckpoint Based Therapy: a review of development in immune checkpoint study and its application. Comb Chem High Throughput Screen. 2017,20(5):430-439. （3）Yao Huang;Jianxing Zeng;Teng Liu;Qingyi Xu;Xianglin Song;Jinhua Zeng*; DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro, Cancer Management and Research, 2020,12: 3247-3255. （4）Yao Huang;Jianxing Zeng;Teng Liu;Xinju Lin;Pengfei Guo;Jinhua Zeng;Weiping Zhou;Jingfeng Liu*; Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma, OncoTargets and Therapy, 2020,13:4559-4567. （5）Xincong Lin#;Yao Huang#;Ying Sun;Xionghong Tan;Jiahe Ouyang;Bixing Zhao;Yingchao Wang;Xiaohua Xing*;Jingfeng Liu*; 4E-BP1Thr46 Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC, Cancer Management and Research, 2020,12:103-115. （6）Yao Huang; Jinhua Zeng; Recent development and applications of nanomaterials for cancer immunotherapy. Nanotechnology Reviews. 2020(9): 382-399. （7）Huang, Y ; Chen, HK; Zeng, YY; Liu, ZQ ; Ma, HD ; Liu, JF.Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection.Frontiers in Oncology，2021,10. （8）Yao Huang , Xiaoyu Huang, Jianxing Zeng and Jun Lin.Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. Frontiers in Oncology，2021,11. （9）Yao Huang, Jianxing Zeng, Teng Liu, Qingyi Xu, Xianglin Song, Jinhua Zeng. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation. Cell Biology International, 2022,46(7): 1089～1097.
授權(quán)實(shí)用新型專(zhuān)利： （1）黃堯，一種帶切割功能的連發(fā)鈦夾，2022.06.15，2022.12.06，202221508094.X （2）黃堯，反向腹腔鏡施夾器，2022.04.26，2023.01.30，ZL 202221085326.5 |
